Spotlight
Topic
Brand Insights
- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Partnerships: Bargaining Biotechs
Article
Pharmaceutical Executive
Pharmaceutical ExecutivePharmaceutical Executive-04-01-2001
Volume 0
Issue 0
Uniondale, New York, USA-Thirty-eight companies submitted proposals to develop OSI-774, OSI Pharmaceuticals' lead cancer candidate, making it the most sought-after compound of 2000. The statistic was revealed with some satisfaction by Myrtle Potter, chief operating officer of Genentech, the joint winner-along with Roche, its majority stockholder-at the Economist Conferences' annual pharmaceuticals conference.
Articles in this issue
Annual Reports: Size Doesn't Matter
Internet DTC - Minding Your P's & Q's
Regulation: Two-Track Plan
Policy: Tectonic Shift
Liberated?
A Matter of Taste
Partnerships: Bargaining Biotechs
Pediatric Mandate
Genentech's Passion for Patients
Regulation: OK After All
Beyond Training
Balancing Haves & Have-Nots
The Changing OTC Landscape
Related Videos
Related Content
Fierce Females in the Life Science Space
March 29th 2024Podcast
In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
